Drug intelligence / Profile preview

bifidobacterium adolescentis cell-free supernatant

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium adolescentis cell-free supernatant is a research compound made up of metabolites and other substances secreted by the bacterium *Bifidobacterium adolescentis*. Often referred to as a postbiotic, this mixture has been investigated in preclinical settings for its potential therapeutic effects. Research has shown its ability to inhibit the growth of colorectal cancer cells and suppress tumor development in organoid models. The supernatant contains various metabolites, including short-chain fatty acids like butyric acid. Its proposed mechanism of action involves the direct inhibition of cancer cell proliferation and modulation of the intestinal microbiota. It has also been studied for its ability to protect against ileal ulcers induced by nonsteroidal anti-inflammatory drugs in animal models. Currently, it is considered a research material and not a commercially developed pharmaceutical product.

Other names: B. adolescentis cell-free supernatant

Beyond the preview

Go deeper on bifidobacterium adolescentis cell-free supernatant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium adolescentis cell-free supernatant.

Explore the full profile